P/E ratio for Organogenesis (ORGO)
P/E ratio as of April 2024 (TTM): 28.8
According to Organogenesis's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 28.7842. At the end of 2022 the company had a P/E ratio of 22.1.
P/E ratio history for Organogenesis from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 22.1 | 77.1% |
| 2021 | 12.5 | -75.13% |
| 2020 | 50.2 | -559.21% |
| 2019 | -10.9 | 3.39% |
| 2018 | -10.6 | -48.31% |
| 2017 | -20.5 | -7.74% |
| 2016 | -22.2 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | -4.67 | -116.21% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | -0.9953 | -103.46% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.